Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24834953 | 0.84 | L3MBTL1 (0.38) | ALDH1A1TP53TSHRL3MBTL1 | |
| SCHEMBL23748228 | 0.79 | IDO1 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL28613803 | 0.76 | NFE2L2 (0.39) | ALDH1A1L3MBTL1 | |
| SCHEMBL24353740 | 0.76 | MAPT (0.38) | L3MBTL1 | |
| SCHEMBL23748157 | 0.76 | — | — | |
| SCHEMBL28620653 | 0.74 | — | — | |
| SCHEMBL23748214 | 0.74 | GAA (0.38) | — | |
| SCHEMBL28627234 | 0.73 | HTR1A (0.39) | — | |
| SCHEMBL16213529 | 0.72 | MAPT (0.39) | TSHRL3MBTL1 | |
| SCHEMBL23748292 | 0.72 | HRH1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | JANSSEN BIOPHARMA INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | JANSSEN BIOPHARMA INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | Janssen Biopharma, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3864020-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | Janssen BioPharma, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195502-A | Macrocyclic influenza endonuclease inhibitors | 詹森生物制药有限公司 | 2021-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | ACE, PNP, FEN1 | ALDH1A1 2073/4885TP53 627/4885TSHR 2251/4885 |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | ACE, FEN1, PNP | ALDH1A1 1487/4885TP53 1012/4885TSHR 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.